NASDAQ:RIGLRigel Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.78 -0.04 (-2.20 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$1.77Now: $1.78▼$1.8550-Day Range$1.78MA: $1.89▼$2.0552-Week Range$1.23Now: $1.78▼$3.10Volume1.57 million shsAverage Volume2.14 million shsMarket Capitalization$300.05 millionP/E RatioN/ADividend YieldN/ABeta1.26 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingRigel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Rigel Pharmaceuticals has a potential upside of 312.0% from its current price of $1.78.Amount of Analyst CoverageRigel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesRigel Pharmaceuticals has received 410 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRigel Pharmaceuticals has received 329 “underperform” votes. (Add your “underperform” vote.)Community SentimentRigel Pharmaceuticals has received 55.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote “Outperform” if you believe RIGL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRigel Pharmaceuticals does not currently pay a dividend.Dividend GrowthRigel Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.72% of the stock of Rigel Pharmaceuticals is held by insiders.Percentage Held by Institutions87.96% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rigel Pharmaceuticals are expected to decrease in the coming year, from ($0.27) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rigel Pharmaceuticals is -11.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rigel Pharmaceuticals is -11.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRigel Pharmaceuticals has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RIGL Previous Symbol CUSIP76655960 CIK1034842 Webwww.rigel.com Phone650-624-1100Debt Debt-to-Equity Ratio0.35 Current Ratio3.73 Quick Ratio3.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$59.29 million Price / Sales5.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book5.56Profitability EPS (Most Recent Fiscal Year)($0.40) Net Income$-66,890,000.00 Net Margins-27.39% Return on Equity-40.15% Return on Assets-18.60%Miscellaneous Employees158 Outstanding Shares168,570,000Market Cap$300.05 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:RIGL Rates by TradingView Receive RIGL News and Ratings via Email Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions How has Rigel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RIGL stock has decreased by 1.7% and is now trading at $1.78. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Rigel Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rigel Pharmaceuticals. When is Rigel Pharmaceuticals' next earnings date? Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Rigel Pharmaceuticals. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported $0.13 EPS for the quarter, hitting the consensus estimate of $0.13. The biotechnology company earned $55.76 million during the quarter, compared to analysts' expectations of $56.94 million. Rigel Pharmaceuticals had a negative return on equity of 40.15% and a negative net margin of 27.39%. View Rigel Pharmaceuticals' earnings history. What price target have analysts set for RIGL? 4 Wall Street analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $7.33 in the next year. This suggests a possible upside of 312.0% from the stock's current price. View analysts' price targets for Rigel Pharmaceuticals. Has Rigel Pharmaceuticals been receiving favorable news coverage? Media coverage about RIGL stock has been trending neutral on Saturday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Rigel Pharmaceuticals. Who are some of Rigel Pharmaceuticals' key competitors? Some companies that are related to Rigel Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Rigel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Geron (GERN), Terra Tech (TRTC), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Verastem (VSTM) and Aurora Cannabis (ACB). Who are Rigel Pharmaceuticals' key executives? Rigel Pharmaceuticals' management team includes the following people: Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)Dr. Thomas A. Raffin, Co-Founder (Age 72) What is Rigel Pharmaceuticals' stock symbol? Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL." Who are Rigel Pharmaceuticals' major shareholders? Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Diversified Trust Co (0.03%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View institutional ownership trends for Rigel Pharmaceuticals. Which major investors are buying Rigel Pharmaceuticals stock? RIGL stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III, and Raul R Rodriguez. View insider buying and selling activity for Rigel Pharmaceuticals. How do I buy shares of Rigel Pharmaceuticals? Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Rigel Pharmaceuticals' stock price today? One share of RIGL stock can currently be purchased for approximately $1.78. How big of a company is Rigel Pharmaceuticals? Rigel Pharmaceuticals has a market capitalization of $300.05 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe. What is Rigel Pharmaceuticals' official website? The official website for Rigel Pharmaceuticals is www.rigel.com. How can I contact Rigel Pharmaceuticals? Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected] This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
